{"disease":{"id":"drug-resistant-focal-seizure","name":"drug resistant focal seizure"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03373383","title":"Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03370120","title":"Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03739840","title":"A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06899230","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"iQure Australia Pty Ltd","has_results":false},{"nct_id":"NCT06388707","title":"A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":8,"lead_sponsor_name":"NaviFUS Corporation","has_results":false},{"nct_id":"NCT05605756","title":"BOTOX Effects on Seizure Severity and Susceptibility","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}